Monday, February 5, 2024

Intelsat and J-AIR Offer the First Free IFEC on Regional Aircraft in Japan

 MCLEAN, Va.

(BUSINESS WIRE)--Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of inflight connectivity (IFC), along with Tokyo-based Japan Airlines Co., Ltd. today announced Intelsat’s connectivity service will launch on the airlines' Embraer E190 aircraft for its subsidiary airline, J-AIR Co. Ltd.


Japan Airlines has installed Intelsat’s 2Ku system on the first of J-AIR’s E190 aircraft and will be installing 13 additional aircraft by autumn 2024. The airline has been offering free wireless entertainment services since 2016. By adding 2Ku, this will make J-AIR the first regional aircraft in Japan to offer inflight entertainment and connectivity (IFEC) services, as well as the first E190 aircraft equipped globally with the Intelsat 2Ku system.


“We have worked closely with Intelsat to deliver the best connectivity experience on Japan Airlines and the JAL group fleet,” said Keisuke Suzuki, SVP, Customer Experience of Japan Airlines. “Intelsat’s capable and reliable 2Ku system will provide miles of entertainment to our customers making J-AIR the first regional aircraft offering the IFC services in Japan.”


“At Intelsat, our mission is to provide quality, reliable connectivity for work and entertainment which is essential for airline partners and passengers alike,” commented Dave Bijur, senior vice president of Commercial for Intelsat Commercial Aviation. “While having wireless entertainment was an excellent first step, J-AIR sees the importance of connectivity as well. Adding 2Ku will enable the same free inflight internet experience they have had since 2017 on the larger jets. For Intelsat, this is a great showcase for other E190 operators around the world who want to offer a free service to all their passengers.”


The service is now available on select flights.


For more information about Intelsat’s commercial aviation connectivity products, visit here.


About Intelsat


As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses, and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com.


About J-AIR Co., Ltd.


J-AIR is an airline based in Osaka, Japan, a subsidiary of Japan Airlines Co., Ltd. and serving for domestic passengers in Japan. The airline has a fleet of 14 tails of E190 aircraft and 18 tails of E170 aircraft.


Follow Us on Social Media:

Twitter | LinkedIn | Facebook | Instagram | YouTube


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20221228005266/en/



Permalink

https://www.aetoswire.com/en/news/401202329325

Contacts

Media:

Melissa Longo - melissa.longo@intelsat.com; +1 240-308-1881

Sunday, February 4, 2024

Belkin Introduces Future Ventures Division for Further Product Innovation and New Category Creation

 


 Future Ventures will investigate new opportunities to build products for every generation

(BUSINESS WIRE) -- Belkin, a leading consumer electronics brand for 40 years, today announced a new division to the company, Future Ventures. This division will focus on opportunities and new avenues for Belkin to explore creative solutions for the modern world including content creation, spatial computing, Artificial Intelligence, robotics, and more. The first two products from this new line are the Auto-Tracking Stand Pro, announced earlier this year at CES 2024, and a new Battery Holder for Apple Vision Pro.

Future Ventures will be comprised of forward-thinking designers, engineers and product managers all in-house at Belkin’s headquarters in El Segundo, CA and in satellite hubs worldwide. Belkin’s longstanding legacy in creating quality and human-centric peripheral mobile and computer accessories is the basis behind this new division, and steadily positions the company for new products and categories for the next generation.

“Belkin has been innovating for over 40 years, and Future Ventures was a clear next step in our plans to continue bringing new ideas to the table,” said Steve Malony, CEO, Belkin. “We know that good ideas come from anywhere, so we are looking everywhere to explore new categories and products that we believe in. Future Ventures opens the door to new markets that Belkin has not typically been part of in previous years. We experienced major success at CES 2024 with our new Auto-Tracking Stand Pro, but this is just the beginning of what this new division is capable of.”

The Auto-Tracking Stand Pro

The world’s first Apple certified Works with DockKit accessory, the Auto-Tracking Stand Pro provides seamless hands-free camerawork for content creators, filmmakers, educators, virtual presenters, social app developers, and more. DockKit’s automated subject tracking technology is designed to follow subjects on camera as they move around their space with 360 degrees of pan and 90 degrees of tilt. Additionally, the Auto-Tracking Stand Pro is made more responsibly with a minimum of 75% PCR materials and sold in plastic-free packaging in line with Belkin’s commitment to find more responsible ways to build products.

The Auto-Tracking Stand Pro is $179.99 USD and is available to pre-order on belkin.com. Media kit is available for download HERE.

Battery Holder for Apple Vision Pro

Designed to keep the Apple Vision Pro Battery secure, the Battery Holder allows for a convenient and versatile hands-free experience. The Battery Holder offers a quick and easy way to clip the battery onto a belt or pants, while the cross-body strap gives those without clip access a great way to secure the battery while using Apple Vision Pro.

The Battery Holder is $49.95 USD and is now available at apple.com. Media kit is available for download HERE.

For more information on Belkin’s products, please visit Belkin.com or follow Belkin on InstagramFacebook, TikTokLinkedIn and X.

About Belkin

Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.

 



Contacts

Media contact
Jen Wei
VP of Global Communications and Corporate Development
comms@belkin.com


vItalian Derby Campaign Kicks Off with Kojiro Hyuga & Others Debuting as New Players Wearing the Juventus Official Uniform “Captain Tsubasa: Dream Team”

 


 KLab Inc., a leader in online mobile games, announced that its head-to-head football simulation game Captain Tsubasa: Dream Team will be holding the Italian Derby Campaign alongside the Serie A Inter vs Juventus match that will be held on February 5, 2024 (JST). See the original press release (https://www.klab.com/en/press/) for more information.

Juventus Selection Transfer

Event Period: Saturday, February 3 16:00 until Saturday, February 17 15:59 (JST/UTC+9)

Filippo Inzars, Davi, Kojiro Hyuga, and Tresaga debut as new players wearing the Juventus official uniform. One SSR player is guaranteed on Steps 3 and 6, and one new SSR player is guaranteed on Step 9.

*There is an SP exchange limit.

Inter Selection Transfer

Event Period: Monday, February 19 16:00 until Monday, March 4 15:59 (JST/UTC+9)

Ryo Ishizaki, Zanetty, and Zlatamović debut as new players wearing the Inter official uniform. One SSR player is guaranteed on Steps 3 and 6, and one new SSR player is guaranteed on Step 9.

*There is an SP exchange limit.

Italian Derby: Event Missions

Event Period: Monday, February 5 16:00 until Monday, February 12 15:59 (JST/UTC+9)

Clear the missions during the event period to receive the following items.

Special Skill Unlock Medals

Carefully Selected Player Transfer Tickets

And more

In addition, an Extreme Event will be held where users can earn points to receive Dreamballs, Formations, and more.

Overview of Captain Tsubasa: Dream Team

Supported OSes:                   Android™ 4.4+, iOS 11.0+, HarmonyOS 2.0+

Genre:                                                Head-to-head football simulation game

Price:                                      Free-to-play (In-app purchases available)

Supported Regions:              Global (Excludes Japan and Mainland China)

Official Website:                                https://www.tsubasa-dreamteam.com/en

Official X Account:               @tsubasaDT_en

Official Facebook Page:                   https://www.facebook.com/tsubasaDTen

Official YouTube Channel:        https://www.youtube.com/channel/UCTgOPO7kIQ35YzB7SBIQoWQ/

Official Discord Channel:                https://discord.gg/6tyEs48

Copyright:                             ©Yoichi Takahashi/SHUEISHA

©Yoichi Takahashi/SHUEISHA/TV TOKYO/ENOKIFILM
            © KLabGames

Download here:

App Store: https://itunes.apple.com/app/id1293738123

Google Play: https://play.google.com/store/apps/details?id=com.klab.captain283.global

AppGallery: https://appgallery.huawei.com/#/app/C105375049



Contacts

Melwyn Abraham - melwyn@matrixdubai.com

Saturday, February 3, 2024

PMI and BAT Announce Global Patent Settlement

 STAMFORD, CT - Friday, 02. February 2024


.


(BUSINESS WIRE) -- Philip Morris International Inc (PMI) (NYSE: PM) is pleased to announce that it has reached a global settlement with British American Tobacco p.l.c. (BAT) that resolves all ongoing patent infringement litigation between the parties related to our heated tobacco and vapor products.


Patent protection is a critical component of the innovation driving PMI’s strategies and the company welcomes this settlement as the best path forward for its business plans.


The settlement includes non-monetary provisions between PMI and BAT that resolve all ongoing global patent infringement litigation, encompassing all related injunctions and exclusion orders, and prevents future claims against current heated tobacco and vapor products. The settlement also allows each party to innovate and introduce product iterations. PMI is committed to continued innovation in reduced-risk products to further advance Tobacco Harm Reduction.


"We are pleased that this matter has been resolved to the mutual satisfaction of both parties,” said Jacek Olczak, Chief Executive Officer. “There is a clear and growing global desire from adults who smoke to choose from a range of smoke-free products, and we believe continued reduced-risk category innovation can accelerate declines in the harms associated with smoking to the benefit of consumers and public health at large - as we continue PMI’s journey to end the sale of cigarettes."


EDITOR’S NOTE


A summary of the settlement between the parties will be available on the website of the Securities and Exchange Commission (SEC) in our Form 8-K filing to be filed today. Our SEC filings are available here.


Forward-Looking & Cautionary Statements


This press release contains projections of future results and goals and other forward-looking statements, including statements regarding expected financial or operational performance; investment strategies; regulatory outcomes; market expectations; and business plans and strategies. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.


PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of COVID-19 on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to produce and commercialize reduced-risk products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our reduced-risk product category's performance.


PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the year ended December 31, 2022, and the Form 10-Q for the third quarter ended September 30, 2023. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.


Philip Morris International: Delivering a Smoke-Free Future


Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match - a leader in oral nicotine delivery - creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products. As of September 30, 2023, PMI's smoke-free products were available for sale in 82 markets, and PMI estimates that approximately 19.7 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 36.2% of PMI’s total third-quarter 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240202036913/en/



Permalink

https://www.aetoswire.com/en/news/0202202437429

Contacts

Philip Morris International

Investor Relations:

Stamford, CT: +1 (203) 904 2410

Lausanne: +41 (0)58 242 4666

Email: InvestorRelations@pmi.com


Media: David Fraser

Lausanne: +41 (0)58 242 4500

Email: David.Fraser@pmi.com


 


Friday, February 2, 2024

Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS

 – Galderma reaffirms its dedication to continued Sculptra innovation and scientific advancement, exploring Sculptra’s regenerative properties and potential use in non-facial treatment areas –


(BUSINESS WIRE) -- Galderma, the emerging pure-play dermatology category leader, is proud to celebrate 25 years of Sculptra®, which enjoys the trust of healthcare professionals and unmatched patient satisfaction. Sculptra is the first and original biostimulator, with a unique PLLA-SCA™ formulation that activates the skin’s natural power to revitalize collagen production for a more youthful appearance.


Sculptra has a unique journey in the aesthetics industry, originating as a volume replenishment treatment in 1999 to improve the life of AIDS patients experiencing facial wasting.1 Sculptra’s applications have evolved over the years to become the multifaceted treatment that it is today. As Galderma’s research and understanding of Sculptra’s unique mode of action and dermatological potential has progressed, Sculptra’s applications have expanded from volumization to include skin firmness, structural support, radiance and overall skin quality. Treatment results last for over two years2 thanks to Sculptra’s unique and proprietary ingredient, PLLA-SCA™, which addresses the root causes of skin aging.


In partnership with leading aesthetic healthcare professionals, Galderma developed the AART™ (Anatomy, Assessment, Range and Treatment) methodology. to create individualized treatments. These treatments are built on patients’ underlying anatomy, a thorough facial assessment and product selection, combined with appropriate injection skills. Leveraging the AART methodology, Sculptra can be further tailored to achieve multiple outcomes according to patients' specific needs, while applying a comprehensive and global approach to skin and overall well-being.


Building on the extensive body of evidence on Sculptra’s mode of action and proven long-lasting efficacy and safety profile, the latest research presented at IMCAS 2024 unveils new potential avenues for Sculptra.


 


“Sculptra has a unique usage history in the aesthetic industry, one that has continually increased in synergy with our ongoing research.

Across the globe, Galderma continues to explore and research new treatment areas and result capabilities, to further extend Sculptra’s

potential whilst reaffirming the brand as a category leader.”


 


GERRY MUHLE

HEAD OF GLOBAL PRODUCT STRATEGY

GALDERMA


 


Recent research shows that, in addition to the well-known collagen stimulation, Sculptra’s PLLA-SCA™ has an effect on more components of the extracellular matrix, including elastin,3 indicating regenerative properties.4 New posters presented at IMCAS also showed that PLLA-SCA™ was well tolerated when Sculptra was used to treat non-facial areas. In addition, Sculptra was studied as a potential treatment for the appearance of cellulite, showing results such as improvement in 100% of subjects, in both thighs, at Months 2, 6, and 12,5 and patients’ rapid return to daily activities.


About Sculptra

Sculptra is the original biostimulator and is clinically proven to stimulate the skin's innate collagen (type I) production to increase skin firmness and radiance, for long-lasting, natural-looking rejuvenated appearance. Sculptra is proven to increase collagen type I by 66.5% after 3 months6 through a process that starts stimulation as early as 5 days after injection. It helps progressively restore the skin’s foundation and natural structural function. Sculptra is proven to achieve natural-looking results that last for more than 2 years.7 Sculptra provides targeted collagen stimulation, with unique treatment protocols developed for each treatment area and to achieve the patients’ desired results.


About Galderma

Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.


References


_________________________________________

1 Douglas Mest, M. a. a. G. H. M., 2010. [Online]. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3013554/

2 Snyder, A., 2023. [Online]. Available at: https://www.researchgate.net/publication/370515491_SculptraR-History_and_how_it_is_best_used_today

3 Christine Guarnieri Munia, M. a. M. M. M. M. S. M. M. P. M. a. L. E. A. M., 2023. [Online]. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286875/

4 Jill Waibel, A randomized, comparative study describing the gene signatures of poly-llactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. IMCAS 2024 poster

5 Sachin M Shridharani 1, G. M. T. 1. T. G. E. 2. T. N. M. 2. C. E. 3., 2021. [Online]. Available at: https://pubmed.ncbi.nlm.nih.gov/33830621/

6 Goldberg D, Guana A, Volk A, Daro-Kaftan E. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915-922.

7 Fabi S. Poster presented at AMWC 2023.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240201863167/en/



Permalink

https://aetoswire.com/en/news/0202202437426

Contacts

For further information:


Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50


Sébastien Cros

Corporate Communications Director

sebastien.cros@galderma.com

+41 79 529 59 85


Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12


Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43


 

Clinique Partners with Icahn School of Medicine at Mount Sinai to Establish the Mount Sinai-Clinique Healthy Skin Dermatology Center

 NEW YORK - Friday, 02. February 2024

New Research Center Aims to Deliver Breakthrough Advancements in Dermatology and Discover Solutions for Healthy and Allergic Skin


(BUSINESS WIRE)--Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center. The Center will develop forward-thinking research in dermatology, exploring the biological underpinnings of how skin ages, skin allergies and inflammatory or eczematous skin conditions, including eczema (or atopic dermatitis) and contact dermatitis. Rooted in a shared mission to conduct dermatological research that improves patients’ lives, the partnership will focus on applicable scientific discovery and leading-edge innovation to modernize allergy science in order to identify innovative solutions for these skin conditions.


Research conducted under the Mount Sinai-Clinique Healthy Skin Dermatology Center aims to uncover scientific findings to accelerate the creation of new topical and systemic treatments that help alleviate allergic skin conditions. The priority is to bridge basic science with practical application in the clinic to improve people’s lives through healthy skin. By investigating healthy skin, along with the skin of those with atopic dermatitis and other allergic skin disorders, the researchers may learn how to significantly slow the visible signs of aging in all people as well as in patients with eczema, who show signs of premature or accelerated aging. Insights from this research aim to spur advances in the field of dermatology and skin health. Additionally, they will inform and inspire Clinique in future product innovation to offer further solutions for people with allergic or sensitive skin.


“As a brand that has offered dermatologist guided solutions and allergy tested solutions since its inception, Clinique is proud to partner with the renowned institution of Icahn Mount Sinai and its team of physician-scientists, led by a world-renowned expert in allergic and inflammatory skin diseases, Dr. Emma Guttman. We are inspired by the team’s dedication to the research and future discoveries of allergic skin and its life impact, including aging. We are energized by our mutual commitment and steadfast belief that great skin can be created and maintained for all. I am confident that this first-of-its-kind partnership will enable groundbreaking research by leading physician-scientists dedicated to advancing allergy science,” Michelle Freyre, President, Global Brands, Clinique.


Dr. Emma Guttman, MD, PhD, Waldman Professor and System Chair, Department of Dermatology at the Icahn School of Medicine, a trailblazer in dermatologic science, has dedicated her career to bridging science with practice intended to improve patients’ lives. Her work has led to novel therapeutic targets for patients suffering from inflammatory skin conditions. Drawing inspiration from her personal and family history of eczema and other allergic conditions, Dr. Guttman has made it her mission to alleviate sensitive skin.


“Years of chronic inflamed skin plays a role in premature aging. Extensive research has helped us understand the molecular map of skin conditions associated with allergy such as eczema and contact dermatitis, and we’re now at a pivotal point in addressing these conditions and more. With Clinique’s support, we will continue to actively explore targeted approaches to reversing eczematous and allergic skin conditions with the goal of creating and sustaining healthy skin. In turn, we want to use this understanding to address and prevent the process of age-related inflammation or ‘inflammaging’ in the first place,” says Dr. Guttman, who also directs the Center of Excellence in Eczema at Mount Sinai and the Laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai.


The laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai has a major focus on atopic dermatitis, contact dermatitis, alopecia areata, and other inflammatory skin diseases. It has made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis, opening the door to new therapeutics. Dr. Guttman’s lab developed the only comprehensive molecular maps of atopic dermatitis, defining skin differentiation and immune-circuits characterizing this disease across phenotypes and ages. This work on atopic dermatitis/eczema has contributed directly to many of the recently developed treatments for this disease, earning Dr. Guttman and her lab a unique place as being a top leader in dermatology and immunology worldwide.


Clinique has a long-standing history of partnering with dermatologists, including its Founding Dermatologist, Norman Orentreich, MD, and incorporating patients’ insights in its innovation since 1968. His children, Catherine Orentreich, MD, and David Orentreich, MD, the brand’s Guiding Dermatologists, continue their father’s legacy for Clinique. Dr. David Orentreich is Assistant Clinical Professor of Dermatology at Icahn Mount Sinai, and he and Dr. Catherine Orentreich are members of the Mount Sinai Dermatology Advisory Board.


In this meaningful mission, Clinique has made a philanthropic commitment of $5 million over seven years for the advancement and evolution of allergy science through the partnership and founding of the Mount Sinai-Clinique Healthy Skin Dermatology Center. The funds will be used to recruit the best and brightest physicians and scientists, and provide resources for the most advanced equipment, clinical and laboratory space, and key support staff. The studies conducted by the Mount Sinai-Clinique Healthy Skin Dermatology Center will include all ages, genders, races and ethnicities, and will also investigate the effects of factors such as diet, exercise, and stress on the skin of healthy people. Mount Sinai predicts that with Clinique’s support, critical breakthroughs will be fast-tracked, from the earliest stages of the multiyear partnership.


About Mount Sinai Health System:

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, more than 400 outpatient practices, more than 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,400 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024.


About Clinique:

In 1968, a beauty editor asked a leading New York City dermatologist, “Can great skin be created?” The answer: yes. And with that yes, Clinique was born. Today Clinique is the #1 Dermatologist Brand in Skincare in the US* and #1 Dermatologist Brand in Makeup in the US**, offering its dermatologist guided, allergy tested solutions for remarkable skin results. The brand is sold in 107 markets worldwide. Clinique’s clinical solutions are informed by years of research, working with dermatologists, scientists, and ophthalmologists. All Clinique formulas are designed to deliver powerful efficacy with rigorous safety —clinically proven, allergy tested, and 100% fragrance free.


*Source: Circana, U.S. Prestige Beauty Total Measured Market, Skincare Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023

**Source: Circana, U.S. Prestige Beauty Total Measured Market, Makeup Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023


Derm Brand is defined as a brand that was founded or developed by a dermatologist and/or is dermatologist recommended.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240202954316/en/



Permalink

https://www.aetoswire.com/en/news/53891079e

Contacts

 

Icahn Mount Sinai: Laura Ruocco-Duran: Laura.Ruocco-Duran@mountsinai.org

Clinique: Dorota Sekulska: DSekulsk@clinique.com

LambdaTest Launches First Edition of Spartan Summit 2024: A Confluence of Testing Titans

SAN FRANCISCO - Thursday, 01. February 2024

LambdaTest announces Spartan Summit 2024, uniting testing experts & enthusiasts for knowledge-sharing & networking in a free online event

(BUSINESS WIRE)--LambdaTest, a leading cloud-based unified testing platform, announces the Spartan Summit 2024, scheduled for February 6th. This free and online event promises a confluence of testing experts and enthusiasts, offering a unique platform for knowledge-sharing and networking.

LambdaTest Spartans is a community advocacy program for innovators, builders, and change-makers in the testing and QA world, including community evangelists dedicated to transforming the industry.

The Spartan Summit brings together LambdaTest Spartans, a community of dedicated ambassadors spanning from testing enthusiasts to seasoned experts. These Spartans drive change in the testing and QA landscape and are the focal point of this annual gathering.

Pricilla Bilavendran, a QA Test Leader at Billennium and also a LambdaTest Spartan, expressed her enthusiasm for the event, stating, "Being a LambdaTest Spartan is such an honor and pleasure for me. When I heard about running a conference only by the Spartans I was amazed by this idea. The ambassador programs rarely have a lot of offerings. You can find selective, curated talks and workshops with many networking opportunities. So, don't miss to be part of this year's Spartan Summit."

The Spartan Summit 2024 features engaging discussions on topics such as web performance metrics, soft skills in test automation, automation tools evaluation, backend microservices ecosystem enhancement with contract testing, and the impact of AI in quality assurance and beyond.

Manoj Kumar, VP of Developer Relations at LambdaTest, said, "The Spartan Summit embodies our commitment to fostering a vibrant testing community by providing a platform where industry leaders, innovators, and enthusiasts can converge. The Summit empowers attendees to share insights, exchange ideas, and collectively shape the future of testing. It's a testament to our dedication to driving innovation and excellence within the testing community, ultimately impacting the industry at large."

Highlights of the Spartan Summit 2024 include the chance to join the esteemed ranks of Spartans, participate in competitions and raffles, and gain valuable insights to shape the future of testing.

To know more about the Spartan Summit, please visit https://www.lambdatest.com/spartans-summit-2024.

About LambdaTest

LambdaTest is an intelligent and omnichannel enterprise execution environment that helps businesses drastically reduce time to market through Just in Time Test Orchestration (JITTO), ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.

    Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 3000+ different browsers, real devices, and operating system environments.
    HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to cut down on quality test time, helping developers build software faster.

For more information, please visit https://lambdatest.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131715435/en/

Permalink
https://www.aetoswire.com/en/news/20240131715435r1

Contacts
 

LambdaTest press office: press@lambdatest.com